Masking the transmembrane region of the amyloid β precursor protein as a safe means to lower amyloid β production
Abstract Introduction Reducing brain levels of both soluble and insoluble forms of amyloid beta (Aβ) remains the primary goal of most therapies that target Alzheimer's disease (AD). However, no treatment has so far resulted in patient benefit, and clinical trials of the most promising drug cand...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-10-01
|
Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
Subjects: | |
Online Access: | https://doi.org/10.1002/trc2.12428 |